06 September 2020: Clinical Research
Plasma β-Endorphin Concentration and Antipsychotic Treatment Outcome in Schizophrenia: 1-Year Follow-Up
Małgorzata Urban-Kowalczyk 1ABDEFG* , Magdalena Kotlicka-Antczak 1BDEF , Dominik Strzelecki 1BDEG , Ewa Rudecka 2BDEF , Janusz Śmigielski 3BCDEDOI: 10.12659/MSM.924307
Med Sci Monit 2020; 26:e924307
Table 1 Characteristics of patient samples.
| Characteristics | Means (±SD) | P value (<0.05) | |
|---|---|---|---|
| Hospitalized patientsN=15 | Non-hospitalized patientsN=10 | ||
| Age (years) | 44.800 (12.049)min=26; max=62 | 41.600 (11.177)min=20; max=5 | 0.512 |
| Sex; Male: Female | 6: 9 | 6: 4 | 0.567 |
| BE1 (ng/mL)* | 0.561 (0.096)min=0.360; max=0.693 | 0.505 (0.112)min=0.327; max=0.645 | 0.193 |
| BE2 (ng/mL)** | 0.678 (0.080)min=0.557; max=0.844 | 0.541 (0.106)min=0.415; max=0.752 | 0.001 |
| Duration of illness (years) | 14.867 (8.927)min=2; max=31 | 11.600 (8.566)min=1; max=32 | – |
| Number of hospitalizations*** | 7.467 (5.383)min=1; max=19 | 5.200 (3.120)min=1; max=11 | – |
| * β-endorphin concentration at study enrollment; ** β-endorphin concentration after 6 weeks of treatment; *** all previous psychiatric hospitalizations. | |||